Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.07, Zacks reports. The firm had revenue of $0.03 million for the quarter.
Enliven Therapeutics Stock Up 2.2 %
Shares of Enliven Therapeutics stock traded up $0.45 on Friday, hitting $20.74. 205,365 shares of the company traded hands, compared to its average volume of 230,869. The company has a 50-day moving average price of $21.59 and a 200 day moving average price of $23.82. Enliven Therapeutics has a 12-month low of $10.90 and a 12-month high of $30.03. The company has a market cap of $1.01 billion, a PE ratio of -10.92 and a beta of 1.04.
Insider Activity
In related news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction on Friday, March 7th. The shares were sold at an average price of $21.44, for a total value of $142,940.48. Following the completion of the sale, the chief operating officer now owns 323,310 shares of the company's stock, valued at approximately $6,931,766.40. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock in a transaction on Friday, December 27th. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50. The disclosure for this sale can be found here. Insiders have sold a total of 47,784 shares of company stock worth $1,092,375 in the last ninety days. Corporate insiders own 29.20% of the company's stock.
Analyst Upgrades and Downgrades
Separately, BTIG Research started coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a "buy" rating and a $42.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $38.25.
Check Out Our Latest Report on Enliven Therapeutics
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
